Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 87
Filtrar
Más filtros

Tipo del documento
Intervalo de año de publicación
1.
J Contemp Dent Pract ; 18(10): 923-926, 2017 Oct 01.
Artículo en Inglés | MEDLINE | ID: mdl-28989131

RESUMEN

BACKGROUND: Luting agents used to fix artificial prostheses, such as fixed partial denture (FPD) to tooth are basically viscous in nature and show chemical reaction for fixation. Postcementation hypersensitivity is a frequent complaint of patients. The present study was conducted to compare postcementation hypersensitivity with zinc phosphate and self-adhesive resin in complete coverage crown. MATERIALS AND METHODS: This study included 30 patients in which 60 porcelein fused to metal crowns was placed. Two metal crowns were placed in each patient in nonantagonis-tic contralateral quadrants. First crown was cemented with zinc phosphate cement, while the other was cemented with self-adhesive resin. Hypersensitivity was evaluated by visual analog scale (VAS) score and by clinical test. For clinical evaluation of sensitivity, hot and cold water was applied to the cervical margin of restoration for 5 seconds and response was recorded. RESULTS: This study consisted of 30 patients in which 60 crowns were given. There was no statistical difference in VAS score of mastication in zinc phosphate cement recorded at baseline, 1 week, 4 weeks, 6 months, 1 year, and 2 years (p > 0.05). Cold response also did not show a significant difference at six time points. Warm response showed slight decrease in subsequent time points but was nonsignificant (p > 0.05). Similarly, with self-adhesive resin cement, VAS score during mastication, hot and cold response was statistically nonsignificant (p > 0.05). CONCLUSION: Postcementation hypersensitivity is a frequent complaint that patient may experience. However, we found no statistically significant difference in both cements tested. CLINICAL SIGNIFICANCE: Postcementation hypersensitivity is an unpleasant sensation experienced by patients. This may affect the success of any prosthesis. Thus, selection of luting agent for cementation plays an important role to eliminate this symptom.


Asunto(s)
Cerámica/uso terapéutico , Coronas , Dermatitis por Contacto/etiología , Fosfatos/uso terapéutico , Cementos de Resina/uso terapéutico , Compuestos de Zinc/uso terapéutico , Cerámica/efectos adversos , Coronas/efectos adversos , Cementos Dentales/efectos adversos , Cementos Dentales/uso terapéutico , Humanos , Fosfatos/efectos adversos , Estudios Prospectivos , Cementos de Resina/efectos adversos , Compuestos de Zinc/efectos adversos
2.
J Nanosci Nanotechnol ; 15(1): 74-84, 2015 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-26328307

RESUMEN

Malignant tumors are the most serious threat to human health. Much research has focused on revealing the characteristics of this disease and developing methods of treatment. Because tumor cells are more sensitive to heat than normal cells, thermotherapy for the treatment of tumors has attracted much attention. In this paper, we presented functional Mn-Zn ferrite nanoparticles with the molecular composition of Mn0.4Zn0.6Fe2O4 as the magnetic response material for the thermotherapy. The suggested Mn-Zn ferrite nanoparticles were with a self-regulation temperature of 43 degrees C which was ideal for tumor thermotherapy. The biocompatibility and anti-tumor effect of this material were well investigated. It was found that the Mn0.4Zn0.6Fe2O4 nanoparticles have no hemolysis activity, no genotoxic effects and cytotoxicity. Its Median Lethal Dose (LD50) arrived at 6.026 g/kg and it did not induce any abnormal clinical signs in laboratory animals. Moreover, the suggested nanoparticles can increase the inhibitory ratio of weight and volume of tumors, cause tumor tissues necrosis and show the therapeutic effect on the xenograft live cancers in vivo. Based on these results, we could envision the valuable application of the Mn0.4Zn0.6Fe2O4 nanoparticles for the practical thermotherapy.


Asunto(s)
Antineoplásicos/toxicidad , Materiales Biocompatibles/toxicidad , Compuestos Férricos/toxicidad , Hipertermia Inducida/métodos , Neoplasias Hepáticas/terapia , Nanopartículas de Magnetita/toxicidad , Compuestos de Zinc/toxicidad , Animales , Antineoplásicos/química , Antineoplásicos/farmacología , Antineoplásicos/uso terapéutico , Materiales Biocompatibles/química , Materiales Biocompatibles/farmacología , Materiales Biocompatibles/uso terapéutico , Peso Corporal/efectos de los fármacos , Línea Celular , Supervivencia Celular/efectos de los fármacos , Femenino , Compuestos Férricos/química , Compuestos Férricos/farmacología , Compuestos Férricos/uso terapéutico , Hemólisis/efectos de los fármacos , Hígado/patología , Neoplasias Hepáticas/patología , Nanopartículas de Magnetita/química , Nanopartículas de Magnetita/uso terapéutico , Masculino , Compuestos de Manganeso/química , Compuestos de Manganeso/farmacología , Compuestos de Manganeso/uso terapéutico , Ratones , Conejos , Compuestos de Zinc/química , Compuestos de Zinc/farmacología , Compuestos de Zinc/uso terapéutico
3.
Cochrane Database Syst Rev ; (11): CD010470, 2014 Nov 26.
Artículo en Inglés | MEDLINE | ID: mdl-25425011

RESUMEN

BACKGROUND: The sense of taste is very much essential to the overall health of the individual. It is a necessary component to enjoying one's food, which in turn provides nutrition to an individual. Any disturbance in taste perception can hamper the quality of life in such patients by influencing their appetite, body weight and psychological well-being. Taste disorders have been treated using different modalities of treatment and there is no consensus for the best intervention. Hence this Cochrane systematic review was undertaken. OBJECTIVES: To assess the effects of interventions for the management of patients with taste disturbances. SEARCH METHODS: We searched the Cochrane Oral Health Group Trials Register (to 5 March 2014), the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library Issue 1, 2014), MEDLINE via OVID (1948 to 5 March 2014), EMBASE via OVID (1980 to 5 March 2014), CINAHL via EBSCO (1980 to 5 March 2014) and AMED via OVID (1985 to 5 March 2014). We also searched the relevant clinical trial registries and conference proceedings from the International Association of Dental Research/American Association of Dental Research (to 5 March 2014), Association for Research in Otolaryngology (to 5 March 2014), the US National Institutes of Health Trials Register (to 5 March 2014), metaRegister of Controlled Trials (mRCT) (to 5 March 2014), World Health Organization's International Clinical Trials Registry Platform (WHO ICTRP) (to 5 March 2014) and International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) Clinical Trials Portal (to 5 March 2014). SELECTION CRITERIA: We included all randomised controlled trials (RCTs) comparing any pharmacological agent with a control intervention or any non-pharmacological agent with a control intervention. We also included cross-over trials in the review. DATA COLLECTION AND ANALYSIS: Two authors independently, and in duplicate, assessed the quality of trials and extracted data. Wherever possible, we contacted study authors for additional information. We collected adverse events information from the trials. MAIN RESULTS: We included nine trials (seven parallel and two cross-over RCTs) with 566 participants. We assessed three trials (33.3%) as having a low risk of bias, four trials (44.5%) at high risk of bias and two trials (22.2%) as having an unclear risk of bias. We only included studies on taste disorders in this review that were either idiopathic, or resulting from zinc deficiency or chronic renal failure.Of these, eight trials with 529 people compared zinc supplements to placebo for patients with taste disorders. The participants in two trials were children and adolescents with respective mean ages of 10 and 11.2 years and the other six trials had adult participants. Out of these eight, two trials assessed the patient reported outcome for improvement in taste acuity using zinc supplements (RR 1.45, 95% CI 1.0 to 2.1; very low quality evidence). We included three trials in the meta-analysis for overall taste improvement (effect size 0.44, 95% CI 0.23 to 0.65; moderate quality evidence). Two other trials described the results as taste acuity improvement and we conducted subgroup analyses due to clinical heterogeneity. One trial described the results as taste recognition improvement for each taste sensation and we analysed this separately. We also analysed one cross-over trial separately using the first half of the results. None of the zinc trials tested taste discrimination. Only one trial tested taste discrimination using acupuncture (effect size 2.80, 95% CI -1.18 to 6.78; low quality evidence).Out of the eight trials using zinc supplementation, four reported adverse events like eczema, nausea, abdominal pain, diarrhoea, constipation, decrease in blood iron, increase in blood alkaline phosphatase, and minor increase in blood triglycerides. No adverse events were reported in the acupuncture trial.None of the included trials could be included in the meta-analysis for health-related quality of life in taste disorder patients. AUTHORS' CONCLUSIONS: We found very low quality evidence that was insufficient to conclude on the role of zinc supplements to improve taste perception by patients, however we found moderate quality evidence that zinc supplements improve overall taste improvement in patients with zinc deficiency/idiopathic taste disorders. We also found low quality evidence that zinc supplements improve taste acuity in zinc deficient/idiopathic taste disorders and very low quality evidence for taste recognition improvement in children with taste disorders secondary to chronic renal failure. We did not find any evidence to conclude the role of zinc supplements for improving taste discrimination, or any evidence addressing health-related quality of life due to taste disorders.We found low quality evidence that is not sufficient to conclude on the role of acupuncture for improving taste discrimination in cases of idiopathic dysgeusia (distortion of taste) and hypogeusia (reduced ability to taste). We were unable to draw any conclusions regarding the superiority of zinc supplements or acupuncture as none of the trials compared these interventions.


Asunto(s)
Terapia por Acupuntura , Trastornos del Gusto/terapia , Compuestos de Zinc/uso terapéutico , Adolescente , Adulto , Niño , Humanos , Calidad de Vida , Ensayos Clínicos Controlados Aleatorios como Asunto , Trastornos del Gusto/diagnóstico , Percepción del Gusto , Compuestos de Zinc/efectos adversos
4.
Nanotechnology ; 24(25): 255101, 2013 Jun 28.
Artículo en Inglés | MEDLINE | ID: mdl-23708194

RESUMEN

Joint therapy is a promising area of study in cancer treatment. In this paper, we prepared Mn-Zn ferrite (Mn0.5Zn0.5Fe2O4) magnetofluid using PEI as a surfactant, and investigated the anticancer effect of Mn0.5Zn0.5Fe2O4 magnetic fluid hyperthermia (MFH) combined with radiotherapy on hepatocellular carcinoma. Both in vitro and in vivo results suggest that this combined treatment with MFH and radiation has a better therapeutic effect than either of them alone. The apoptotic rate and necrotic rate of the combined treatment group was 38.80 and 25.20%, respectively. In contrast, it was only 7.49 and 3.62% in the radiation-alone group, 15.23 and 7.90% in the MFH-alone group, only 3.52 and 2.16% in the blank control group, and 23.56 and 27.56% in the adriamycin group. The cell proliferation inhibition rate of the combined treatment group (88.5%) was significantly higher than that of the radiation-alone group (37.5%), MFH-alone group (60.6%) and adriamycin group (70.6%). The tumor volume inhibition and mass inhibition rate of the combined treatment group was 87.62 and 88.62%, respectively, obviously higher than the 41.04 and 34.20% of the radiation-alone group, 79.87 and 77.92% of the MFH-alone group and 71.76 and 66.87% of the adriamycin group. It is therefore concluded that this combined application of MFH and radiation can give good synergistic and complementary effects, which offers a viable approach for treatment of cancer.


Asunto(s)
Carcinoma Hepatocelular/terapia , Compuestos Férricos/uso terapéutico , Hipertermia Inducida/métodos , Neoplasias Hepáticas/terapia , Magnetismo/métodos , Compuestos de Manganeso/uso terapéutico , Nanopartículas/uso terapéutico , Compuestos de Zinc/uso terapéutico , Animales , Apoptosis/efectos de la radiación , Carcinoma Hepatocelular/patología , Carcinoma Hepatocelular/radioterapia , Proliferación Celular/efectos de los fármacos , Terapia Combinada/métodos , Compuestos Férricos/química , Células Hep G2 , Humanos , Hígado/patología , Hígado/efectos de la radiación , Neoplasias Hepáticas/patología , Neoplasias Hepáticas/radioterapia , Compuestos de Manganeso/química , Ratones , Ratones Desnudos , Nanopartículas/química , Nanopartículas/ultraestructura , Polietileneimina/química , Tensoactivos/química , Compuestos de Zinc/química
5.
J Clin Periodontol ; 40(5): 505-13, 2013 May.
Artículo en Inglés | MEDLINE | ID: mdl-23489103

RESUMEN

AIMS: The aim of this study was to assess the efficacy of mouthrinses formulations in oral malodour. MATERIAL & METHODS: This single-centre, double-blind, randomized, parallel group clinical trial compared the efficacy of Halita™ and meridol(®) with and without zinc lactate versus negative and positive control. Volunteers with confirmed oral malodour (18/group) rinsed with one mouthrinse during 7 days (15 ml, 2x/day for 1 min.). 15 min. after a first rinse (masking effect), and after 7 days (therapeutic effect) the change in organoleptic scores and level of sulphur compounds was recorded. RESULTS: All rinses showed a masking effect (OLS 1 to 2 values reduced), only the rinses with antimicrobial ingredients showed a therapeutic effect (OLS 1 to 1.5 value less). The addition of zinc resulted in a more pronounced masking effect. Halita™ and meridol(®) with zinc showed the best therapeutic effect. CONCLUSION: Although the masking effect of the rinses can be attributed partially to a dilution and the effect of aromas, the therapeutic effect should be linked to the anti-microbial action of active ingredients and counter action of zinc ions on VSC. A complete resolution of the unpleasant breath by additional mechanical intervention remains to be proven.


Asunto(s)
Halitosis/prevención & control , Antisépticos Bucales/uso terapéutico , Aminas/química , Aminas/uso terapéutico , Antiinfecciosos/química , Antiinfecciosos/uso terapéutico , Antiinfecciosos Locales/química , Antiinfecciosos Locales/uso terapéutico , Carga Bacteriana/efectos de los fármacos , Cetilpiridinio/química , Cetilpiridinio/uso terapéutico , Química Farmacéutica , Clorhexidina/análogos & derivados , Clorhexidina/química , Clorhexidina/uso terapéutico , Cromatografía de Gases/instrumentación , Método Doble Ciego , Combinación de Medicamentos , Femenino , Halitosis/metabolismo , Humanos , Sulfuro de Hidrógeno/análisis , Lactatos/química , Lactatos/uso terapéutico , Masculino , Persona de Mediana Edad , Antisépticos Bucales/química , Oxidantes/química , Oxidantes/uso terapéutico , Saliva/microbiología , Compuestos de Sulfhidrilo/análisis , Fluoruros de Estaño/química , Fluoruros de Estaño/uso terapéutico , Lengua/microbiología , Resultado del Tratamiento , Compuestos Orgánicos Volátiles/análisis , Compuestos de Zinc/química , Compuestos de Zinc/uso terapéutico
6.
Am J Dent ; 26(4): 180-4, 2013 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-24693626

RESUMEN

PURPOSE: To evaluate the in vivo effect of chewing gum containing allyl isothiocyanate alone, and in combination with zinc salts on reduction of the level of volatile sulfur compounds responsible for oral malodor. METHODS: 15 healthy volunteers between the ages of 20-50 chewed either an experimental gum or a placebo gum for 12 minutes. Their mouth air was analyzed for volatile sulfur compounds by a gas chromatograph at baseline, immediately after chewing, and at 60, 120 and 180 minutes after treatment. RESULTS: The study revealed that allyl isothiocyanate, a constituent of mustard seed extract, can effectively reduce the concentration of volatile sulfur compounds in mouth air. Chewing gum containing 0.1% zinc lactate and 0.01% of allyl isothiocyanate eliminated 89%, 55.5%, 48% and 24% of the total VSC concentration immediately after chewing and at 1, 2, and 3 hours after chewing, respectively.


Asunto(s)
Goma de Mascar , Halitosis/prevención & control , Isotiocianatos/uso terapéutico , Planta de la Mostaza , Extractos Vegetales/uso terapéutico , Semillas , Adulto , Cromatografía de Gases , Estudios Cruzados , Femenino , Estudios de Seguimiento , Halitosis/metabolismo , Humanos , Sulfuro de Hidrógeno/análisis , Isotiocianatos/administración & dosificación , Masculino , Persona de Mediana Edad , Placebos , Extractos Vegetales/administración & dosificación , Método Simple Ciego , Compuestos de Sulfhidrilo/análisis , Factores de Tiempo , Compuestos Orgánicos Volátiles/análisis , Adulto Joven , Compuestos de Zinc/administración & dosificación , Compuestos de Zinc/uso terapéutico
7.
Int J Dent Hyg ; 11(1): 35-40, 2013 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-22672130

RESUMEN

OBJECTIVES: To assess the effectiveness of three different mouthrinses--chlorhexidine, triclosan + sodium fluoride and chlorhexidine + triclosan + sodium fluoride + zinc chloride--on plaque, calculus, gingivitis and stains and to evaluate the occurrence of adverse effects with these three treatments. METHODS: Forty-eight healthy subjects participated in a double-blind, randomized, parallel experiment and were randomly allocated to any one of the three experimental mouthrinses: group A (0.2% chlorhexidine (CHX) gluconate), group B (0.03% triclosan + 0.025% sodium fluoride (NaF) + 12% ethyl alcohol) or group C (0.2% CHX + 0.3% triclosan + 0.3% NaF + 0.09% Zn chloride (ZnCl(2)). All the subjects were assessed for gingivitis, plaque, supragingival calculus and extrinsic stains at baseline and at the end of the 21-day experimental period. RESULTS: There was a significant difference (P = 0.046) in the effectiveness for the prevention of gingivitis and plaque, with subjects of group A and group C presenting least and highest gingival and plaque scores, respectively. Significant differences (P = 0.03) were observed for the accumulation of supragingival calculus where the deposition of calculus in group A was nearly double that of the group B, and group B was most effective in the prevention of supragingival calculus. Highest deposition of extrinsic stains was in the group A followed by group C and group B. There was no significant difference between the three treatments for adverse events' occurrence. CONCLUSIONS: CHX mouthrinse was most effective in controlling plaque and gingivitis but caused greatest deposition of extrinsic stains. Supragingival calculus deposition was least in triclosan + NaF group followed by CHX + triclosan + NaF + ZnCl(2) and CHX. More than half of the subjects reported adverse events during the experimental phase.


Asunto(s)
Antiinfecciosos Locales/uso terapéutico , Clorhexidina/análogos & derivados , Cálculos Dentales/prevención & control , Placa Dental/prevención & control , Gingivitis/prevención & control , Antisépticos Bucales/uso terapéutico , Decoloración de Dientes/inducido químicamente , Triclosán/uso terapéutico , Antiinfecciosos Locales/efectos adversos , Cariostáticos/efectos adversos , Cariostáticos/uso terapéutico , Clorhexidina/efectos adversos , Clorhexidina/uso terapéutico , Cloruros/efectos adversos , Cloruros/uso terapéutico , Índice de Placa Dental , Método Doble Ciego , Femenino , Estudios de Seguimiento , Humanos , Masculino , Enfermedades de la Boca/inducido químicamente , Antisépticos Bucales/efectos adversos , Índice de Higiene Oral , Índice Periodontal , Prurito/inducido químicamente , Fluoruro de Sodio/efectos adversos , Fluoruro de Sodio/uso terapéutico , Resultado del Tratamiento , Triclosán/efectos adversos , Adulto Joven , Compuestos de Zinc/efectos adversos , Compuestos de Zinc/uso terapéutico
8.
J Clin Periodontol ; 39(11): 1056-64, 2012 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-22924756

RESUMEN

AIMS: This study compared the antimicrobial effects of three commercial dentifrice formulations: sodium fluoride/triclosan/copolymer (TCN/C), stannous fluoride/sodium hexametaphosphate/zinc lactate (SnF(2)/SHMP) and sodium fluoride (NaF). MATERIALS AND METHODS: Thirty-five adults (15 men and 20 women; average age 33 years and pockets <5 mm) completed this double-blind, triple-crossover study. After washout, baseline samples from four sites, plaque, saliva, tongue and buccal mucosa, were collected and evaluated for six microbial types, anaerobes, Streptococci, Actinomyces, hydrogen-sulphide (H(2) S)-producing bacteria, Fusobacteria and Veillonella. A specific dentifrice was randomly assigned for twice-daily use for 13 days. On day 14, 12 h after brushing, samples were collected for microbiological evaluations. Alternate dentifrices followed this identical protocol. RESULTS: For all four oral sites and six organisms evaluated in each site, the TCN/C demonstrated significant reductions (49-83%) as compared with the other treatments (p < 0.01). The SnF(2)/SHMP group showed significant reductions of 14-43% for 14 of 24 outcomes as compared with the NaF group (p < 0.01), with no differences in 10 outcomes. CONCLUSIONS: The TCN/C dentifrice formulation consistently demonstrated significant reductions for a range of microorganisms in diverse oral sites in comparison with the NaF, or the SnF(2)/SHMP dentifrice formulations as seen 12 h after brushing.


Asunto(s)
Antiinfecciosos Locales/uso terapéutico , Carga Bacteriana/efectos de los fármacos , Cariostáticos/uso terapéutico , Dentífricos/uso terapéutico , Boca/microbiología , Adolescente , Adulto , Anciano , Estudios Cruzados , Dentífricos/química , Método Doble Ciego , Combinación de Medicamentos , Femenino , Humanos , Ácido Láctico/uso terapéutico , Masculino , Persona de Mediana Edad , Boca/efectos de los fármacos , Mucosa Bucal/efectos de los fármacos , Mucosa Bucal/microbiología , Fosfatos/uso terapéutico , Fluoruro de Sodio/uso terapéutico , Fluoruros de Estaño/uso terapéutico , Pastas de Dientes/química , Pastas de Dientes/uso terapéutico , Triclosán/uso terapéutico , Adulto Joven , Zinc/uso terapéutico , Compuestos de Zinc/uso terapéutico
9.
Biol Pharm Bull ; 35(9): 1496-501, 2012.
Artículo en Inglés | MEDLINE | ID: mdl-22975500

RESUMEN

The purpose of this research is improvement of therapeutic treatment for periodontitis by using lipophilic and/or hydrophilic zinc materials. The sample suspension injections were prepared from zinc octanate (C8Zn), zinc stearate (C18Zn), zinc sulfate hepta-hydrate (ZnSO4) and tricalcium phosphate (ZnTCP) containing 6.17 w/w% zinc. After administrating of all injections to around alveolar bone of zinc-deficient osteoporosis rats, plasma Zn concentration, bone mineral content (BMC) of jawbone, BMC and bone mechanical strength (BMS) of femur and permeability tests for hairless rat stripped skin were measured as therapeutic scores. BMC and BMS were measured by using an X-ray computing tomography and the three-point bending method, respectively. The body weight, plasma Zn concentrations and the area under curve (AUC) for Zn of C8Zn, C18Zn and ZnTCP group rats were higher than those of control group, but those of ZnSO4 group were not changed. BMC of alveolar bone and femur and BMS of femur for C8Zn and C18Zn groups for 12 weeks were significantly higher than those of the control group, but those of ZnSO4 group were not changed. Stripped rat skin permeability treated by the hydrophilic creams containing C8Zn was 5-times higher than that of ZnTCP.


Asunto(s)
Huesos/efectos de los fármacos , Enfermedades Carenciales/tratamiento farmacológico , Osteoporosis/tratamiento farmacológico , Periodontitis/metabolismo , Oligoelementos/uso terapéutico , Compuestos de Zinc/uso terapéutico , Zinc/uso terapéutico , Animales , Área Bajo la Curva , Peso Corporal/efectos de los fármacos , Densidad Ósea , Huesos/metabolismo , Enfermedades Carenciales/sangre , Enfermedades Carenciales/metabolismo , Femenino , Fémur/metabolismo , Interacciones Hidrofóbicas e Hidrofílicas , Osteoporosis/metabolismo , Periodontitis/tratamiento farmacológico , Ratas , Ratas sin Pelo , Ratas Sprague-Dawley , Piel , Absorción Cutánea , Oligoelementos/sangre , Oligoelementos/deficiencia , Zinc/sangre , Zinc/deficiencia , Compuestos de Zinc/sangre
10.
Caries Res ; 45(6): 581-9, 2011.
Artículo en Inglés | MEDLINE | ID: mdl-22156703

RESUMEN

New toothpastes with anti-erosion claims are marketed, but little is known about their effectiveness. This study investigates these products in comparison with various conventional NaF toothpastes and tin-containing products with respect to their erosion protection/abrasion prevention properties. In experiment 1, samples were demineralised (10 days, 6 × 2 min/day; citric acid, pH 2.4), exposed to toothpaste slurries (2 × 2 min/day) and intermittently stored in a mineral salt solution. In experiment 2, samples were additionally brushed for 15 s during the slurry immersion time. Study products were 8 conventional NaF toothpastes (1,400-1,490 ppm F), 4 formulations with anti-erosion claims (2 F toothpastes: NaF + KNO(3) and NaF + hydroxyapatite; and 2 F-free toothpastes: zinc-carbonate-hydroxyapatite, and chitosan) and 2 Sn-containing products (toothpaste: 3,436 ppm Sn, 1,450 ppm F as SnF(2)/NaF; gel: 970 ppm F, 3,030 ppm Sn as SnF(2)). A mouth rinse (500 ppm F as AmF/NaF, 800 ppm Sn as SnCl(2)) was the positive control. Tissue loss was quantified profilometrically. In experiment 1, most NaF toothpastes and 1 F-free formulation reduced tissue loss significantly (between 19 and 42%); the Sn-containing formulations were the most effective (toothpaste and gel 55 and 78% reduction, respectively). In experiment 2, only 4 NaF toothpastes revealed significant effects compared to the F-free control (reduction between 29 and 37%); the F-free special preparations and the Sn toothpaste had no significant effect. The Sn gel (reduction 75%) revealed the best result. Conventional NaF toothpastes reduced the erosive tissue loss, but had limited efficacy regarding the prevention of brushing abrasion. The special formulations were not superior, or were even less effective.


Asunto(s)
Cariostáticos/uso terapéutico , Fluoruro de Sodio/uso terapéutico , Fluoruros de Estaño/uso terapéutico , Abrasión de los Dientes/prevención & control , Erosión de los Dientes/prevención & control , Pastas de Dientes/química , Pastas de Dientes/uso terapéutico , Aminas/uso terapéutico , Análisis de Varianza , Carbonatos/uso terapéutico , Quitosano/uso terapéutico , Humanos , Hidroxiapatitas/uso terapéutico , Nanopartículas , Nitratos/uso terapéutico , Compuestos de Potasio/uso terapéutico , Estadísticas no Paramétricas , Compuestos de Estaño/uso terapéutico , Abrasión de los Dientes/etiología , Remineralización Dental/métodos , Cepillado Dental/efectos adversos , Compuestos de Zinc/uso terapéutico
11.
Int Dent J ; 61 Suppl 3: 28-32, 2011 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-21762152

RESUMEN

OBJECTIVES: To introduce a variable which directly measures maintenance of gingival health. DESIGN: The maintenance of gingival health index (MGHI) is based on the change in score at each tooth site compared to a reference visit for a clinical index (eg MGI or BI). For a subject the number of sites that (1) improve-NDEC, (2) show no change-NNOCHG or (3) worsen-NINC in score are determined. Then the MGHI for a subject is defined as (NDEC+NNOCHNG)/NINC. RESULTS: This method was applied to two clinical studies and both studies demonstrated significantly better maintenance of gingival health in those subjects who received the experimental 0.1% w/w o-cymen-5-ol/ 0.6% w/w ZnCl2 dentifrice compared to the 0.204% w/w sodium fluoride control dentifrice based on a gingival and a bleeding clinical index. CONCLUSION: The MGHI is a useful measure to assess the maintenance of gingival health. It is very applicable to the maintenance of gingival health study designs as it directly looks at a measurement of maintaining the health of tooth sites. It also provides a meaningful measure of the relative effectiveness of dentifrice products to the dental practitioner.


Asunto(s)
Dentífricos/uso terapéutico , Gingivitis/prevención & control , Índice Periodontal , Ensayos Clínicos Controlados Aleatorios como Asunto , Análisis de Varianza , Cloruros/uso terapéutico , Dentífricos/química , Humanos , Fenoles/uso terapéutico , Fluoruro de Sodio/uso terapéutico , Compuestos de Zinc/uso terapéutico
12.
Int Dent J ; 61 Suppl 3: 1-3, 2011 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-21762148

RESUMEN

Oral hygiene habits are strongly associated with general health behaviours; good oral self care should result in good dental health. Clinical dental hygiene services have limited long range probability of success if the patient is not diligent in the daily procedures of personal care to remove and control dental plaque. Therefore, it is important to help make the individual aware of their own ability to control and maintain good oral health after a dental prophylaxis through oral care instruction and the use of select antimicrobials to maintain the gingival health. This paper reviews the evidence outlining the relative roles of prophylaxis and correct oral self-care in maintaining gingival health.


Asunto(s)
Placa Dental/prevención & control , Dentífricos/química , Gingivitis/prevención & control , Higiene Bucal/métodos , Antiinfecciosos Locales/uso terapéutico , Cloruros/uso terapéutico , Profilaxis Dental , Dentífricos/uso terapéutico , Gingivitis/terapia , Humanos , Fenoles/uso terapéutico , Prevención Secundaria , Compuestos de Zinc/uso terapéutico
13.
Int Dent J ; 61 Suppl 3: 13-20, 2011 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-21762150

RESUMEN

OBJECTIVES: To assess the ability of 0.1%w/w o-cymen-5-ol/ 0.6%w/w zinc chloride dentifrice to maintain gingival health compared to a sodium fluoride control dentifrice. DESIGN: Following a baseline examination, subjects went through a regimen to bring them to a high level of gingival health. This included a professional prophylaxis supported by oral hygiene instruction prior to commencing study treatment. Subjects brushed twice daily for 12 weeks with either the test or control dentifrice. Examinations for gingival inflammation (MGI), bleeding and plaque were performed after 6 and 12 weeks. RESULTS: 224 subjects were included in the efficacy analysis. Relative to the sodium fluoride/ silica control dentifrice group the o-cymen-5-ol/ zinc chloride dentifrice exhibited statistically significant reductions (p<0.0001) in MGI, bleeding and plaque of 12.3%, 18.5% and 13.2% respectively after six weeks and 38.1%, 37.8% and 24.2% after 12 weeks. CONCLUSION: The results of the present clinical study demonstrate that the use of the 0.1%w/w o-cymen-5-ol/ 0.6%w/w zinc chloride dentifrice over a 12 week period provides a statistically significant benefit in maintaining gingival health compared to a sodium fluoride control dentifrice.


Asunto(s)
Cloruros/uso terapéutico , Dentífricos/uso terapéutico , Gingivitis/prevención & control , Fenoles/uso terapéutico , Compuestos de Zinc/uso terapéutico , Adolescente , Adulto , Anciano , Análisis de Varianza , Placa Dental/prevención & control , Índice de Placa Dental , Dentífricos/química , Método Doble Ciego , Femenino , Humanos , Masculino , Persona de Mediana Edad , Índice Periodontal , Fluoruro de Sodio/uso terapéutico , Cepillado Dental , Adulto Joven
14.
Int Dent J ; 61 Suppl 3: 21-7, 2011 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-21762151

RESUMEN

OBJECTIVES: To assess the ability of 0.1%w/w o-cymen-5-ol/ 0.6%w/w zinc chloride gel to foam dentifrice to maintain gingival health compared to a sodium fluoride control dentifrice. DESIGN: Following a baseline examination, subjects went through a regimen to bring them to a high level of gingival health. This involved a professional dental prophylaxis supported by oral hygiene instruction prior to commencing study treatment. Subjects brushed twice daily for 12 weeks with either the test or control dentifrice. Examinations for gingival inflammation (MGI), bleeding and plaque were performed after 12 weeks. RESULTS: 205 subjects were included in the efficacy analysis. Relative to the sodium fluoride/ silica control dentifrice group the o-cymen-5-ol/ zinc chloride gel to foam dentifrice exhibited statistically significant reductions (p<0.0001) in MGI, bleeding and plaque of 32.2%, 26.3% and 20.7% respectively after 12 weeks. CONCLUSION: The results of the present clinical study demonstrate that the use of the 0.1%w/w o-cymen-5-ol/ 0.6%w/w zinc chloride gel to foam dentifrice over a 12 week period provides a statistically significant benefit in maintaining gingival health compared to a sodium fluoride control dentifrice.


Asunto(s)
Cloruros/uso terapéutico , Dentífricos/uso terapéutico , Gingivitis/prevención & control , Fenoles/uso terapéutico , Compuestos de Zinc/uso terapéutico , Adolescente , Adulto , Anciano , Análisis de Varianza , Placa Dental/prevención & control , Índice de Placa Dental , Profilaxis Dental , Dentífricos/química , Femenino , Humanos , Masculino , Persona de Mediana Edad , Índice Periodontal , Método Simple Ciego , Fluoruro de Sodio/uso terapéutico , Adulto Joven
15.
Int Dent J ; 61 Suppl 3: 60-6, 2011 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-21762157

RESUMEN

OBJECTIVES: To assess the ability of a 0.1% w/w o-cymen-5-ol/ 0.6% w/w zinc chloride/ sodium fluoride dentifrice to control oral malodour compared to a sodium fluoride control dentifrice. DESIGN: Following baseline measurement of oral volatile sulfur compounds (VSCs), the subjects brushed twice daily for 1 week with either the test or control dentifrice. The VSC concentration in breath samples was monitored up to 12 hours post-treatment, by gas chromatography (GC). RESULTS: 75 subjects were included in the efficacy analysis. Relative to the sodium fluoride control dentifrice group the o-cymen-5-ol/ zinc chloride/ sodium fluoride dentifrice exhibited statistically significant reductions (P<0.0001) in hydrogen sulfide, methyl mercaptan and total measured VSCs immediately and after 1, 2, 3 and 12 (overnight) hours post-treatment. CONCLUSION: The results of the present clinical study demonstrated that the use of the 0.1% w/w o-cymen-5-ol/ 0.6% w/w zinc chloride/ sodium fluoride dentifrice over a one week period provided a statistically significant benefit in controlling oral malodour for up to 12 hours post-treatment compared to a sodium fluoride control dentifrice.


Asunto(s)
Cloruros/uso terapéutico , Dentífricos/uso terapéutico , Halitosis/prevención & control , Fenoles/uso terapéutico , Compuestos de Zinc/uso terapéutico , Pruebas Respiratorias , Cromatografía de Gases/métodos , Estudios Cruzados , Dentífricos/química , Método Doble Ciego , Femenino , Humanos , Sulfuro de Hidrógeno/análisis , Masculino , Persona de Mediana Edad , Fluoruro de Sodio/uso terapéutico , Compuestos de Sulfhidrilo/análisis
16.
Int Dent J ; 61 Suppl 3: 74-80, 2011 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-21762159

RESUMEN

Fluoride toothpastes in conjunction with tooth brushing are used to clean teeth, control plaque build-up and for anti-caries benefits. Toothpastes are designed with attractive flavours and appearances to encourage regular prolonged use to maximise these benefits. The incorporation of additional ingredients into toothpaste is a convenient way to provide supplementary protection that fits into people's everyday oral care routine. Such ingredients should not compromise the primary health benefits of toothpaste nor discourage its use. o-Cymen-5-ol and zinc chloride have been incorporated into a sodium fluoride (NaF)/silica toothpaste at 0.1%w/w and 0.6%w/w respectively to provide additional benefits. These include improved gingival health maintenance, in terms of the reduction of plaque, gingival index and bleeding, and an immediate and long lasting reduction in volatile sulfur compounds (VSCs) measured on breath. These benefits can be attributed to the antimicrobial and neutralisation actions of the toothpaste. The use of established fluoride models demonstrated no compromise in NaF bioavailability. The toothpaste was formulated without compromising product aesthetics. The combination of o-cymen-5-ol and zinc chloride in toothpaste gave superior maintenance of gingival health and reduction in malodour related VSCs without compromising the primary health benefits of the toothpaste or diminishing attributes preferred for the product's use.


Asunto(s)
Cloruros/uso terapéutico , Gingivitis/prevención & control , Halitosis/prevención & control , Fenoles/uso terapéutico , Pastas de Dientes/química , Compuestos de Zinc/uso terapéutico , Cariostáticos/uso terapéutico , Química Farmacéutica , Placa Dental/prevención & control , Humanos , Dióxido de Silicio , Fluoruro de Sodio/uso terapéutico , Desmineralización Dental/prevención & control , Remineralización Dental , Pastas de Dientes/uso terapéutico
17.
Int Dent J ; 61 Suppl 3: 55-9, 2011 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-21762156

RESUMEN

AIM: To evaluate the ability of two experimental toothpastes containing 0.1%w/w o-cymen-5-ol, 0.6%w/w ZnCl2 and 0.320%w/w NaF to reduce demineralisation of sound human enamel compared with control toothpastes. METHODS: Study 1: Specimens were treated with toothpaste slurries, followed by alternating periods in demineralising and neutral solutions. Demineralisation was assessed using surface microhardness (SMH). Study 2: Specimens were subjected to a 14 day cycling regime of alternating demineralisation/remineralisation with two toothpaste treatments per day, before and after demineralisation. Demineralisation was assessed by cross-sectional microhardness and mineral loss (ΔZ) was calculated. Test toothpastes were a) 0%w/w or 0.002%w/w NaF placebo, b) 0.055%w/w or 0.149%w/w NaF (dose response), c) 0.320%w/w NaF marketed product, d & e) 0.1%w/w o-cymen-5-ol, 0.6%w/w ZnCl2 and 0.320%w/w NaF (experimental toothpastes). RESULTS: Study 1: Mean±SE % of baseline hardness values were a) 48.0±2.1a, b) 66.7±1.7b, c) 82.9±1.9c, d) 91.7±1.4d and e) 94.6±2.1d. Study 2: Mean±SE ΔZ values were a) 2114±187a, b) 1206±132b, c) 303±89c, d) 19±73c, and e) -10±55c. Letters represent different statistical groupings (P<0.05). CONCLUSION: In study 1, both experimental toothpastes were statistically superior to the marketed product and in study 2; they were at least as effective as the marketed product at reducing caries lesion development.


Asunto(s)
Cloruros/uso terapéutico , Fenoles/uso terapéutico , Desmineralización Dental/prevención & control , Pastas de Dientes/uso terapéutico , Compuestos de Zinc/uso terapéutico , Análisis de Varianza , Cariostáticos/farmacología , Cariostáticos/uso terapéutico , Cloruros/farmacología , Dureza/efectos de los fármacos , Humanos , Concentración de Iones de Hidrógeno , Fenoles/farmacología , Fluoruro de Sodio/farmacología , Fluoruro de Sodio/uso terapéutico , Remineralización Dental , Pastas de Dientes/química , Pastas de Dientes/farmacología , Compuestos de Zinc/farmacología
18.
Compend Contin Educ Dent ; 32(1): 70-6, 2011.
Artículo en Inglés | MEDLINE | ID: mdl-21462625

RESUMEN

This review summarizes research that has assessed the effectiveness of various antimicrobial-containing dentifrices in preventing and/or reducing a number of oral health problems facing our patients today. The results of these studies indicate that, when compared with a conventional fluoride dentifrice, the triclosan/copolymer/fluoride dentifrice is the one with the most evidence to support its ability to deliver significant oral health benefits with no adverse effects. The benefits maybe summarized as follows: improved levels ofsupragingival plaque control; improved gingival health; reducedlikelihood of gingivitis progressing to periodontitis; arrest progression of periodontitis; prevention of supragingival calculus; and reduction in oral malodor. With increased interest in the association of oral health with systemic health, this dentifrice is well-positioned to help reduce the likelihood of gingivitis establishing itself and possibly developing into periodontitis (Figure 1). It also has the potential to have beneficial effects on general health because of its anti-inflammatory properties. Based on the results presented in this article, it is clear that the general population can derive significant clinical benefits from the daily use of a triclosan/copolymer/fluoride dentifrice. The dental profession should feel confident to recommend its use to patients to improve oral health and maintain or promote overall health.


Asunto(s)
Placa Dental/terapia , Dentífricos/uso terapéutico , Maleatos/uso terapéutico , Periodontitis/terapia , Polietilenos/uso terapéutico , Triclosán/uso terapéutico , Antiinfecciosos Locales/uso terapéutico , Antiinflamatorios no Esteroideos/uso terapéutico , Cloruros/uso terapéutico , Caries Dental/terapia , Combinación de Medicamentos , Humanos , Ácido Silícico/uso terapéutico , Fluoruros de Estaño/uso terapéutico , Pastas de Dientes/uso terapéutico , Compuestos de Zinc/uso terapéutico
19.
Gan To Kagaku Ryoho ; 38(13): 2603-6, 2011 Dec.
Artículo en Japonés | MEDLINE | ID: mdl-22189226

RESUMEN

Mucositis is one of the most frequent side effects induced by chemotherapy that damages the patients' QOL and response rate. The efficacy of Rebamipide and Polaprezinc mouthwash and uptake was evaluated. Nine patients who underwent chemotherapy and had some complaints related with mucositis were included as subjects. Rebamipide (300 mg) and Polaprezinc (150 mg) mouthwashing and uptake were performed by the subjects 4 times per day. Macroscopic examination and symptom research were performed until three months after beginning this medication. Macroscopic mucositis was shown in 5 patients previously and 4 patients improved. Seven patients had symptomatic improvement(p=0. 018). Rebamipide and Polaprezinc mouthwash and uptake is effective for patients who have mucositis induced by chemotherapy.


Asunto(s)
Alanina/análogos & derivados , Antineoplásicos/efectos adversos , Carnosina/análogos & derivados , Antisépticos Bucales/uso terapéutico , Mucositis/tratamiento farmacológico , Neoplasias , Compuestos Organometálicos/uso terapéutico , Quinolonas/uso terapéutico , Anciano , Alanina/uso terapéutico , Antineoplásicos/uso terapéutico , Carnosina/uso terapéutico , Femenino , Humanos , Masculino , Persona de Mediana Edad , Mucositis/inducido químicamente , Neoplasias/tratamiento farmacológico , Calidad de Vida , Organización Mundial de la Salud , Compuestos de Zinc/uso terapéutico
20.
J Oleo Sci ; 70(4): 541-548, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-33814514

RESUMEN

Two mixed-ligand complexes on the basis of L ligand [L = 3,6-bis(imidazol-1-yl)pyridazine] have been prepared under the solvothermal reaction conditions via the Zn(II) salts reacting with the ligands of L in the existence of two positional isomerous carboxylic acid ligands and their chemical formula respectively are [Zn5(L)(1,2-BDC)4(µ3-OH)2] n (1, 1,2-H2BDC = 1,2-benzenedicarboxylic acid ) and {[Zn4(L)2(1,3-HBDC) (1,3-BDC)(µ3-OH)4]·ClO4·3H2O} n (2, 1,3-H2BDC = 1,3-benzenedicarboxylic acid). The inhibitory influence of the two compounds against the inflammatory response in periodontium was evaluated by measuring the inflammatory cytokines releasing with ELISA detection kit. The results of ELISA assay indicated that compound 1 showed much stronger inhibitory influences than compound 2 against the inflammatory cytokines releasing. In addition to this, the suppression activity of the compounds against the survival gene of Porphyria gingivalis was detected via the real time Reverse Transcription-Polymerase Chain Reaction, and the results suggested that compound 1 could evidently suppresses the survival gene expression of Porphyria gingivalis, which is much better than the biological activity of compound 2. Above all, compound 1 was more outstanding than compound 2 on chronic periodontitis treatment by inhibiting the Porphyria gingivalis survival.


Asunto(s)
Fenómenos Fisiológicos Bacterianos/genética , Periodontitis Crónica/tratamiento farmacológico , Periodontitis Crónica/microbiología , Complejos de Coordinación/farmacología , Complejos de Coordinación/uso terapéutico , ARN Polimerasas Dirigidas por ADN/genética , ARN Polimerasas Dirigidas por ADN/metabolismo , Expresión Génica/efectos de los fármacos , Genes Bacterianos/genética , Periodoncio/metabolismo , Periodoncio/microbiología , Porfirias/genética , Compuestos de Zinc/farmacología , Compuestos de Zinc/uso terapéutico , Animales , Complejos de Coordinación/química , Cristalización , Citocinas/metabolismo , Modelos Animales de Enfermedad , Perros , Ensayo de Inmunoadsorción Enzimática , Mediadores de Inflamación/metabolismo , Conformación Molecular , Polímeros , Compuestos de Zinc/química
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA